Fund:Key Science and Technology Research Projects in Key Areas of the Corps (No. 2018AB019)
Abstract
Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis (MTB), which severely endangers human health. Tuberculosis is one of the major infectious diseases causing harm and death to people globally. China has among the highest burden of TB worldwide. China’s TB prevention and control efforts are facing many problems and challenges. The current TB prevention and control service system and control capacity in China cannot meet the prevention and control needs. At present, the most common and effective vaccine to prevent tuberculosis is Bacillus Calmette-Guérin (BCG). However, because of the relatively low protective effect of BCG against pulmonary tuberculosis infection in adolescents and adults, as well as changes in external factors, BCG faces challenges in meeting the urgent needs of preventing and controlling tuberculosis in humans. Currently, research and development of a new TB vaccine is particularly urgent and important. This article introduces the live attenuated vaccine VPM1002 vaccine, protein/adjuvant vaccine H4/H56:IC31 vaccine, viral vector vaccine, adenovirus vector vaccine and other vaccines that have entered clinical trials. It additionally describes the current status of research on anti-TB immune mechanisms to provide a reference for future tuberculosis control, and it discusses ideas for the future development of new TB vaccines. This article should have important reference value for the development and innovation of TB vaccines in China.
AtmakuriK, Penn-NicholsonA, TannerR, et al. Meeting report: 5th Global Forum on TB Vaccines, 20-23 February 2018, New Delhi India[J]. , 2018, 113: 55-64. DOI: 10.1016/j.tube.2018.08.013[本文引用:1]
[3]
RakshitS, AhmedA, AdigaV, et al. BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA-Indian adults[J]. , 2019, 4(24): e130540. DOI: 10.1172/jci.insight.130540[本文引用:1]
MéndezsamperioP. Global efforts in the development of vaccines for tuberculosis: Requirements for improved vaccines against Mycobacterium tuberculosis[J]. , 2016, 84(4): 204-210. DOI: 10.1111/sji.12465[本文引用:1]
[6]
GrodeL, SeilerP, BaumannS, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin[J]. , 2005, 115(9): 2472-2479. DOI: 10.1172/JCI24617[本文引用:1]
[7]
NieuwenhuizenNE, KulkarniPS, ShaligramU, et al. The recombinant bacille calmette-guerin vaccine VPM1002: ready for clinical efficacy testing[J]. , 2017, 8: 1147. DOI: 10.3389/fimmu.2017.01147[本文引用:2]
[8]
VogelzangA, PerdomoC, ZedlerU, et al. Central memory $CD_4^+$ T cells are responsible for the recombinant bacillus calmette-guérin ΔureC: :hly vaccine’s superior protection against tuberculosis[J]. , 2014, 210(12): 1928-1937. DOI: 10.1093/infdis/jiu347[本文引用:1]
[9]
DeselC, DorhoiA, Band ermannS, et al. Recombinant BCG DeltaureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses[J]. , 2011, 204(10): 1573-1584. DOI: 10.1093/infdis/jir592[本文引用:1]
[10]
André GLoxton, Julia K. Knaul, Leand erGrode, et al. Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa[J]. , 2017, 24(2): e00439-16. DOI: 10.1128/cvi.00439-16[本文引用:1]
[11]
SaigaH, NieuwenhuizenN, GengenbacherM, et al. The recombinant BCG ΔureC: :hly vaccine targets the AIM2 inflammasome to induce autophagy and inflammation[J]. , 2015, 211(11): 1831-1841. DOI: 10.1093/infdis/jiu675[本文引用:1]
[12]
CounoupasC, PintoR, NagalingamG, et al. Protective efficacy of recombinant BCG over-expressing protective, stage-specific antigens of Mycobacterium tuberculosis[J]. , 2018, 36(19): 2619-2629. DOI: 10.1016/j.vaccine.2018.03.066[本文引用:1]
[13]
CounoupasC, PintoR, NagalingamG, et al. Mycobacterium tuberculosis components expressed during chronic infection of the lung contribute to long-term control of pulmonary tuberculosis in mice[J]. , 2016, 1: e16012. DOI: 10.1038/npjvaccines.2016.12[本文引用:1]
[14]
CounoupasC, Pinto RNagalingamG, et al. Delta inulin-based adjuvants promote the generation of polyfunctional $CD_4^+$ T cell responses and protection against Mycobacterium tuberculosis infection[J]. , 2017, 7(1): 8582. DOI: 10.1038/s41598-017-09119-y[本文引用:1]
[15]
BrosetE, SaubiN, GuitartN, et al. MTBVAC-Based TB-HIV vaccine is safe, elicits HIV-T cell responses, and protects against Mycobacterium tuberculosis in mice[J]. , 2019, 13: 253-264. DOI: 10.1016/j.omtm.2019.01.014[本文引用:1]
[16]
SpertiniF, AudranR, ChakourR, et al, Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: A rand omised, double-blind, controlled phase I trial[J]. , 2015, 3(12): 953-962. DOI: 10.1016/S2213-2600(15)00435-X[本文引用:1]
[17]
AguiloN, Gonzalo-AsensioJ, Alvarez-ArguedasS, et al. Reactogenicity to major tuberculosisantigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis[J]. , 2017, 8: e16085. DOI: 10.1038/ncomms16085[本文引用:1]
[18]
JesusGA, DessislavaM, CarlosM, et al. MTBVAC: attenuating the human pathogen of tuberculosis (TB) toward a promising vaccine against the TB epidemic[J]. , 2017, 8: 1803. DOI: 10.3389/fimmu.2017.01803[本文引用:1]
[19]
ClarkSimon, LanniFaye, MarinovaDessislava, et al. Revaccination of guinea pigs with the live attenuated Mycobacterium tuberculosis vaccine MTBVAC improves BCG’s protection against tuberculosis[J]. , 2017, 216(5): 525-533. DOI: 10.1093/infdis/jix030[本文引用:1]
[20]
OttenhoffTH, DohertyTM, van DisselJT, et al. First in humans: a new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses[J]. , 2010, 6(12): 1007-1015. DOI: 10.4161/hv.6.12.13143[本文引用:1]
GeldenhuysH, MearnsH, MilesDJ, et al. The tuberculosis vaccine H4: IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A rand omized controlled trial[J]. , 2015, 33(30): 3592-3599. DOI: 10.1016/j.vaccine.2015.05.036[本文引用:2]
[23]
AboutorabianS, HakimiJ, BoudetF, et al. A high ratio of IC31 adjuvant to antigen is necessary for H4 TB vaccine immunomodulation[J]. , 2015, 11(6): 1449-1455. DOI: 10.1080/21645515.2015.1023970[本文引用:1]
[24]
NorrbyM, VesikariT, LindqvistL, et al. Safety and immunogenicity of the novel H4: IC31 tuberculosis vaccine cand idate in BCG-vaccinated adults: Two phase I dose escalation trials[J]. , 2017, 35(12): 1652-1661. DOI: 10.1016/j.vaccine.2017.01.055[本文引用:1]
[25]
NemesE, GeldenhuysH, RozotV, et al. Prevention of M. tuberculosis infection with H4: IC31 Vaccine or BCG Revaccination[J]. , 2018, 379(2): 138-149. DOI: 10.3410/f.733620530.793549119[本文引用:1]
[26]
LinPL, DietrichJ, TanE, et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection[J]. , 2012, 122(1): 303-314. DOI: 10.1172/JCI46252[本文引用:2]
[27]
SulimanS, LuabeyaAKK, GeldenhuysH, et al. Dose optimization of H56: IC31 Vaccine for TB endemic populations: a double-blind, placebo-controlled, dose-selection trial[J]. , 2019, 199(2): 220-231. DOI: 10.1164/rccm.201802-0366OC[本文引用:2]
[28]
LuabeyaAK, KaginaBM, TamerisMD, et al. First-in-human trial of the post-exposure tuberculosis vaccine H56: IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults[J]. , 2015, 33(33): 4130-4140. DOI: 10.1016/j.vaccine.2015.06.051[本文引用:2]
[29]
BekkerLG, DintweO, Fiore-Gartland A, et al. A phase 1b rand omized study of the safety and immunological responses to vaccination with H4: IC31, H56: IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa[J]. , 2020, 21: e100313. DOI: 10.1016/j.eclinm.2020.100313[本文引用:1]
[30]
MontoyaJ, SolonJA, CunananSRC, et al. A rand omized, controlled dose-finding phase II study of the M72/AS01 cand idate tuberculosis vaccine in healthy PPD-positive adults[J]. , 2013, 33(8): 1360-1375. DOI: 10.1007/s10875-013-9949-3[本文引用:2]
[31]
Mushtaqahmed, Shyamalathirunavukkarasu, BruceARosa, et al. Immune correlates of tuberculosis disease and risk translate across species [J]. , 2020, 12(528): eaay0233. DOI: 10.1126/scitranslmed.aay0233[本文引用:1]
[32]
KumarasamyN, PoongulaliS, BollaertsA, et al. A rand omized, controlled safety, and immunogenicity trial of the M72/AS01 cand idate tuberculosis vaccine in HIV-positive indian adults[J]. , 2016, 95(3): 1-10. DOI: 10.1097/MD.0000000000002459[本文引用:1]
[33]
ChaSB, KimWS, KimJS, et al. Pulmonary immunity and durable protection induced by the ID93/GLA-SE vaccine cand idate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K[J]. , 2016, 34(19): 2179-2187. DOI: 10.1016/j.vaccine.2016.03.029[本文引用:1]
[34]
BaldwinSL, ReeseVA, HuangPW, et al. Protection and long-lived immunity induced by the ID93/GLA-SE vaccine cand idate against a Clinical Mycobacterium tuberculosis Isolate[J]. , 2016, 23(2): 137-147. DOI: 10.1128/cvi.00458-15[本文引用:1]
[35]
ColerRN, DayTA, EllisR, et al. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial[J]. , 2018, 3(1): 34. DOI: 10.1038/s41541-018-0057-5[本文引用:1]
[36]
Dubois CauwelaertN, DesbienAL, HudsonTE, et al. The TLR4 agonist vaccine adjuvant, GLA-SE, requires canonical and atypical mechanisms of action for TH1 induction[J]. , 2016, 11: 1-14. DOI: 10.1371/journal.pone.0146372[本文引用:1]
[37]
ZhengJ, ChenL, LiuL, et al. Proteogenomic analysis and discovery of immune antigens in Mycobacterium vaccae[J]. , 2017, 16(9): 1578-1590. DOI: 10.1074/mcp.m116.065813[本文引用:1]
[38]
SoundaryaJSV, RanganathanUD, TripathySP. Current trends in tuberculosis vaccine[J]. , 2019, 75(1): 18-24. DOI: 10.1016/j.mjafi.2018.12.013[本文引用:1]
[39]
KaufmannSH. Tuberculosis vaccines: time to think about the next generation[J]. , 2013, 25(2): 172-181. DOI: 10.1016/j.smim.2013.04.006[本文引用:1]
[40]
XiaoT, LiX, YanY, et al. Cross-reactive immune responses to Mycobacterium vaccae, Mycobacterium tuberculosis and Bacillus Calmette-Guerin[J]. , 2019, 39(3): 212-216. DOI: DOI:10.3760/cma.j.issn.0254-5101.2019.03.010[本文引用:1]
[41]
ReberSO, SieblerPH, DonnerNC, et al. Immunization with a heat-killed preparation of the environmental bacterium Mycobacterium vaccae promotes stress resilience in mice[J]. , 2016, 113(22): e3130-e3139. DOI: 10.1073/pnas.1600324113[本文引用:1]
[42]
SharmaA, EqubalMJ, Pand eyS, et al. Immunodominant protein MIP_05962 from Mycobacterium indicus pranii displays chaperone activity[J]. , 2017, 284(9): 1338-1354. DOI: 10.1111/febs.14057[本文引用:1]
[43]
RawatKD, ChaharM, PvjR, et al. Immunoprophylaxis in Guinea pigs with Mycobacterium indicus pranii (Mw) in combination with stand ard chemotherapy of M. tuberculosis infection improves lung pathology[J]. , 2016, 6(5): e1000230. DOI: 10.4172/2161-1068.1000230[本文引用:2]
[44]
Alexand erDC, TurenneCY. " Mycobacterium indicus pranii" is a strain of Mycobacterium intracellulare[J]. , 2015, 6(. 2): e00013-e00015. DOI: 10.1128/mBio.00013-15[本文引用:1]
[45]
ScribaTJ, KaufmannSH, Henri LambertP, et al. Vaccination against tuberculosis with whole cell mycobacterial vaccines[J]. , 2016, 214(5): 659-664. DOI: 10.3410/f.726392815.793537891[本文引用:1]
[46]
CastejonM, MenéndezMC, ComasI, et al. Whole-genome sequence analysis of the Mycobacterium avium complex and proposal of the transfer of Mycobacterium yongonense to Mycobacterium intracellulare subsp. yongonense subsp. Nov[J]. , 2018, 68(6): 1998-2005. DOI: 10.1099/ijsem.0.002767[本文引用:1]
GuptaAnanya, SaqibMohd, SaqibMohd, et al. Mycobacterium indicus pranii Induced Memory T-Cells in lung airways are sentinels for improved protection against M. tb infection[J]. , 2019, 10: 2359. DOI: 10.3389/fimmu.2019.02359[本文引用:1]
[49]
SharmaA, SaqibM, SheikhJA, et al. Mycobacterium indicus pranii protein MIP_05962 induces Th1 cell mediated immune response in mice[J]. , 2018, 308(8): 1000-1008. DOI: 10.1016/j.ijmm.2018.08.008[本文引用:1]
[50]
NagpalPS, KesarwaniA, SahuP, et al. Aerosol immunization by alginate coated mycobacterium (BCG/MIP) particles provide enhanced immune response and protective efficacy than aerosol of plain mycobacterium against M. tb. H37Rv infection in mice[J]. , 2019, 19(1): 568. DOI: 10.1186/s12879-019-4157-2[本文引用:1]
[51]
SinghB, SaqibM, ChakrabortyA, et al. Lipoarabinomannan from Mycobacterium indicus pranii shows immunostimulatory activity and induces autophagy in macrophages[J]. , 2019, 14(10): e0224239. DOI: 10.1371/journal.pone.0224239[本文引用:1]
[52]
PrabowoSA, PainterH, ZelmerA, et al. RUTI vaccination enhances inhibition of mycobacterial growth ex vivo and induces a shift of monocyte phenotype in mice[J]. , 2019, 10: 894. DOI: 10.3389/fimmu.2019.00894[本文引用:1]
[53]
LimJL, KohVHQ, ChoSSL, et al. Harnessing the Immunomodulatory Properties of Bacterial Ghosts to Boost the Anti-mycobacterial Protective Immunity[J]. , 2019, 10: 2737 DOI: 10.3389/fimmu.2019.02737[本文引用:1]
[54]
PennisiM, RussoG, SgroiG, et al. Predicting the artificial immunity induced by RUTI vaccine against tuberculosis using universal immune system simulator (UISS)[J]. , 2019, 20(6): 504. DOI: 10.1186/s12859-019-3045-5[本文引用:1]
[55]
von ReynCF, LaheyT, ArbeitRD, et al. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A rand omized, controlled trial of DAR-901[J]. , 2017, 12(5): e0175215. DOI: 10.1371/journal.pone.0175215[本文引用:1]
[56]
MasonouT, HokeyDA, LaheyT, et al. $CD_4^+$ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A rand omized, placebo-controlled trial[J]. , 2019, 14(5): e0217091. DOI: 10.1371/journal.pone.0217091[本文引用:2]
[57]
LaheyT, LaddyD, HillK, et al. Immunogenicity and protective efficacy of the DAR-901 booster vaccine in a murine model of tuberculosis[J]. , 2016, 11(12): e0168521. DOI: 10.1371/journal.pone.0168521[本文引用:1]
[58]
SantosuossoM, McCormickS, RoedigerE, et al. Mucosal luminal manipulation of T cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization[J]. , 2007, 178(4): 2387-2395. DOI: 10.4049/jimmunol.178.4.2387[本文引用:1]
[59]
Diaz-San SegundoF, MontielNA, SturzaDF, et al. Combination of Adt-O1Manisa and Ad5-boIFNλ3 induces early protective immunity against foot-and -mouth disease in cattle[J]. , 2016, 499: 340-349. DOI: 10.1016/j.virol.2016.09.027[本文引用:1]
[60]
MetcalfeHJ, SteinbachS, JonesGJ, et al. Protection associated with a TB vaccine is linked to increased frequency of Ag85A-specific $CD_4^+$ T cells but no increase in avidity for Ag85A[J]. , 2016, 34(38): 4520-4525. DOI: 10.1016/j.vaccine.2016.07.055[本文引用:1]
[61]
MetcalfeHJ, BiffarL, SteinbachS, et al. Ag85A-specific $CD_4^+$ T cell lines derived after boosting BCG-vaccinated cattle with Ad5-85A possess both mycobacterial growth inhibition and anti-inflammatory properties[J]. , 2018, 36(20): 2850-2854. DOI: 10.1016/j.vaccine.2018.03.068[本文引用:2]
[62]
StylianouE, GriffithsKL, PoyntzHC, et al. Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A[J]. , 2015, 33(48): 6800-6808. DOI: 10.1016/j.vaccine.2015.10.017[本文引用:1]
[63]
WilkieM, SattiI, MinhinnickA, et al. A phase I trial evaluating the safety and immunogenicity of a cand idate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults[J]. , 2020, 38(4): 779-789. DOI: 10.1016/j.vaccine.2019.10.102[本文引用:1]
[64]
HussainA, SinghS, DasS, et al. Nanomedicines as drug delivery carriers of anti-tubercular drugs: from pathogenesis to infection control[J]. , 2019, 16(5): 400-429. DOI: 10.2174/1567201816666190201144815[本文引用:1]
[65]
CoppolaM, van den EedenSJF, RobbinsN, et al. Vaccines for leprosy and tuberculosis: opportunities for shared research, development, and application[J]. , 2018, 9: 308. DOI: 10.3389/fimmu.2018.00308[本文引用:1]
[66]
MendyJ, JarjuS, HeslopR, et al. Changes in Mycobacterium tuberculosis-specific immunity with influenza co-infection at time of TB diagnosis[J]. , 2019, 10: 3093. DOI: 10.3389/fimmu.2018.03093[本文引用:1]
[67]
TaniguchiK, TakiiT, YamamotoS, et al. Reactivation of immune responses against Mycobacterium tuberculosis by boosting with the CpG oligomer in aged mice primarily vaccinated with Mycobacterium bovis BCG[J]. , 2013, 10(1): 25-25. DOI: 10.1186/1742-4933-10-25[本文引用:1]
[68]
BekaleRB, Du PlessisSM, HsuNJ, et al. Mycobacterium tuberculosis and interactions with the host immune system: Opportunities for Nanoparticle Based Immunotherapeutics and Vaccines[J]. , 2019, 6(1): 8. DOI: 10.1007/s11095-018-2528-9[本文引用:1]
[69]
CooperAM, KhaderSA. The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis[J]. , 2010, .226(1): 191-204. DOI: 10.1111/j.1600-065x.2008.00702.x[本文引用:1]
[70]
RedfordPS, MurrayPJ, O’GarraA. The role of IL-10 in immune regulation during M. tuberculosis infection[J]. , 2011, 4(3): 261-270. DOI: 10.1038/mi.2011.7[本文引用:1]
[71]
SzpakowskiP, BietF, LochtC, et al. Dendritic cell activity driven by recombinant Mycobacterium bovis BCG producing human IL-18, in healthy BCG vaccinated adults[J]. , 2015, 2015(2): 359153. DOI: 10.1155/2015/359153[本文引用:1]
[72]
LaiR, JeyanathanM, AfkhamiS, et al. CD11b+ dendritic cell-mediated anti- Mycobacterium tuberculosis Th1 activation is counterregulated by CD103+ dendritic cells via IL-10[J]. , 2018, 200(5): 1746-1760. DOI: 10.4049/jimmunol.1701109[本文引用:1]
[73]
HatanoR, OhnumaK, YamamotoJ, et al. CD26-mediated co-stimulation in human $CD_8^+$ T cells provokes effector function via pro‐inflammatory cytokine production[J]. , 2013, 138(2): 165-172. DOI: 10.1111/imm.12028[本文引用:1]
RechG, VilaplanaC, VelascoJ, et al. Draft genome sequences of Mycobacterium setense type strain DSM-45070 and the nonpathogenic strain manresensis, isolated from the bank of the cardener river in Manresa, Catalonia, Spain[J]. , 2015, 3(1): e01485-14. DOI: 10.1128/genomeA.01485-14[本文引用:1]
[76]
MontanéE, BarriocanalAM, ArellanoAL, et al. Pilot, double-blind, rand omized, placebocontrolled clinical trial of the supplement food Nyaditum resae in adults with or without latent TB infection: Safety and immunogenicity[J]. , 2017, 12(2): e0171294. DOI: 10.1371/journal.pone.0171294[本文引用:1]
[77]
CardonaP, Marzo-EscartinE, TapiaG, et al. Oral Administration of heat-killed Mycobacterium manresensis delays progression toward active tuberculosis in C3HeB/FeJ Mice[J]. , 2015, 6: 1482. DOI: 10.3389/fmicb.2015.01482[本文引用:1]
[78]
EFSA Panel on Nutrition, Novel foods and food allergens (NDA), TurckD, et al. Safety of heat-killed Mycobacterium setense manresensis as a novel food pursuant to Regulation (EU) 2015/2283[J]. , 2019, 17(11): e05824. DOI: 10.2903/j.efsa.2019.5824[本文引用:1]
[79]
BilleskovRolf, Tan EsterlinaV, CangMarjorie, et al. Testing the H56 vaccine delivered in 4 different adjuvants as a BCG-booster in a non-human primate model of tuberculosis[J]. , 2016, 11(8): e0161217. DOI: 10.1371/journal.pone.0161217[本文引用:1]
[80]
Van RhijnI, MoodyDB. Donor unrestricted T cells: a shared human T cell response[J]. , 2015, 195(5): 1927-1932. DOI: 10.4049/jimmunol.1500943[本文引用:1]
[81]
Larrouy-MaumusG, LayreE, ClarkS, et al. Protective efficacy of a lipid antigen vaccine in a guinea pig model of tuberculosis[J]. , 2017, 35(10): 1395-1402. DOI: 10.1016/j.vaccine.2017.01.079[本文引用:1]
[82]
SulimanS, MurphyM, MusvosviM, et al. MR1-independent activation of human mucosal-associated invariant T cells by Mycobacteria[J]. , 2019, 203(11): 2917-2927. DOI: 10.4049/jimmunol.1900674[本文引用:1]
[83]
PerdomoC, ZedlerU, KühlAA, et al. Mucosal BCG vaccination induces protective lung-resident memory T cell populations against tuberculosis(Article)[J]. , 2016, 7(6): e01686-16. DOI: 10.1128/mBio.01686-16[本文引用:1]
[84]
BullNC, StylianouE, KavehDA, et al. Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1+ KLRG1- $CD_4^+$ T cells[J]. , 2019, 12(2): 555-564. DOI: 10.1038/s41385-018-0109-1[本文引用:1]
[85]
KaufmannE, SanzJ, DunnJL, et al. BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis[J]. , 2018, 172(1-2): 176-190. DOI: 10.1016/j.cell.2017.12.031[本文引用:1]